Researchers from A*STAR's Institute of Molecular and Cell Biology in Singapore have become the first to discover and characterize a human protein called Bax-beta, which can potentially cause the death of cancer cells and lead to new approaches in cancer treatment. The finding is published in the January 16 report of the journal, Molecular Cell.
Detection of Bax-beta has eluded scientists until now. Victor Yu, the principal investigator of the research team at IMCB, said: "our research findings reveal that Bax-beta protein levels are normally kept at essentially undetectable levels in healthy cells by the protein degradation machine in cells known as the 'proteasomes'. The proteasomes are there to keep the lethal Bax-beta in check. This is exciting - if the proteasome-mediated degradation of Bax-beta could be inhibited specifically in cancer cells, it could cause the harmful cancer cells to go through apoptosis."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze